Dermatology Review
facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2025
vol. 112
 
Share:
Share:
abstract:
Review article

Plasma Marker YKL-40 in Psoriasis Patients

Martyna Biadasiewicz
1
,
Monika Kalicka
1
,
Wiktor Kruczek
1
,
Karolina Perlak
1
,
Aleksandra Frątczak 
2
,
Karina Polak
2
,
Bartosz Miziołek
2
,
Beata Bergler-Czop
2

  1. Students’ Scientific Association at the Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
  2. Department of Dermatology, Medical University of Silesia, Katowice, Poland
Dermatol Rev/Przegl Dermatol 2025, 112, 183-190
Online publish date: 2025/08/30
View full text Get citation
 
PlumX metrics:
Introduction
YKL-40, also known as chitinase-3-like protein 1, is an inflammatory and tissue remodeling marker that is elevated in various inflammatory diseases, including psoriasis.

Methods
A comprehensive literature review of the PubMed and Embase databases from their inception to January 2025 identified 13 original studies evaluating the role of YKL-40 in the progression of psoriasis.

Results
Increased serum levels of YKL-40 have been consistently observed in psoriasis patients. Studies have demonstrated a strong correlation between its levels and the severity of clinical manifestations, such as the extent of skin involvement and the Psoriasis Area and Severity Index score and treatment response, particularly following NB-UVB therapy.

Conclusions
YKL-40 shows potential as a biomarker for psoriasis, aiding in disease pathogenesis, severity evaluation, and treatment response, but further research is needed to clarify its role and consistency in association with other inflammatory markers.

keywords:

chitinase-3-like protein 1, psoriasis



Quick links
© 2025 Termedia Sp. z o.o.
Developed by Bentus.